The purchase price includes $75 million in cash and $75 million in Repligen shares, in addition to performance-based earnouts over the next three years.
Repligen said Avitide is expected to contribute about $10 million of revenue in 2022, be accretive to adjusted earnings per share in 2023, strengthen its proteins business and move it into the affinity resin products market for gene therapy.
Repligen will fund the deal, which is expected to close in Q3, with cash on hand.
Price: 296.06, Change: -0.34, Percent Change:
|Jazz Pharma Doses First Patient in Late-Stage Combo ...|
|Update: Barnes & Noble Education Fiscal Q2 Gains Tra...|
|Bitcoin Miner Griid Infrastructure to go Public in M...|
|--Saratoga Investment Raises Quarterly Dividend to $...|
|StoneCo Shares Decline Following Banco Santander Dow...|